What's Happening?
Biomodal, a life sciences technology company, is set to present its 6-base multiomics sequencing solution, duet evoC, at the Festival of Genomics and Biodata London 2026. Dr. Sophie Kirschner from AstraZeneca will showcase how this technology improves
the sensitivity of liquid biopsy tests for early-stage colorectal cancer detection. The solution distinguishes between canonical DNA bases and two epigenetic markers, 5-methylcytosine and 5-hydroxymethylcytosine, in cell-free DNA. This advancement offers a significant improvement over traditional methods that often miss these critical biomarkers. The presentation will highlight findings from a study that demonstrated enhanced diagnostic accuracy by combining these epigenetic measurements.
Why It's Important?
The development of more sensitive diagnostic tools for early-stage cancer detection is crucial in improving patient outcomes. Biomodal's technology could revolutionize how early-stage colorectal cancer is diagnosed, potentially leading to earlier interventions and better survival rates. This advancement underscores the growing importance of genomics and precision oncology in transforming cancer care. By providing more accurate diagnostic tools, healthcare providers can tailor treatments more effectively, reducing unnecessary procedures and improving the quality of life for patients.
What's Next?
The presentation at the Festival of Genomics and Biodata will likely attract attention from researchers and healthcare professionals interested in adopting this technology. As the technology gains recognition, it may lead to further collaborations and studies to validate its effectiveness across different cancer types. The success of this technology could also prompt other companies to invest in similar multiomics approaches, potentially accelerating advancements in cancer diagnostics.
